Brussels, 05/04/2007 (Agence Europe) - EURORDIS, an umbrella group representing more than 300 associations at EU level and the interests of patients affected by rare diseases, was quick to react to the termination of the negotiation process between the European Parliament, Council and Commission on a draft regulation on a centralised EU authorisation system for new therapies derived from cell and tissue engineering. EURORDIS says the decision by the rapporteur, Slovak Christian Democrat...